Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on three azenosertib monotherapy studies: Phase 1 ZN-c3-001, Phase 2 DENALI, and Phase 2 TETON due to two recent deaths in the DENALI study. Despite this setback, Zentalis remains optimistic about azenosertib's potential benefits, having treated over 500 patients with the drug. The company has completed enrollment for Cohort 1b of the DENALI study and plans to present the results later this year. Zentalis will also share findings from other studies and provide further updates following the resolution of the clinical hold. A conference call is scheduled for June 18, 8:00 am ET to discuss these developments.
Zentalis Pharmaceuticals announced on June 3, 2024, that its Compensation Committee granted new employees non-qualified stock options to purchase 20,000 shares under the 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). The exercise price is $11.40 per share, matching the closing price on the grant date. These options will vest over four years, with 25% vesting after one year and the rest monthly over the subsequent three years. The 2022 Inducement Plan aims to attract individuals new to Zentalis, promoting their long-term commitment to the company.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical firm, will participate in the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET. The company will host a fireside chat, with a live webcast and an archived recording accessible via their website. Zentalis specializes in developing small molecule therapeutics targeting cancer's fundamental biological pathways.
Zentalis Pharmaceuticals has appointed Dr. Luke Walker to its Board of Directors. Dr. Walker, currently the Chief Medical Officer at Harpoon Therapeutics, brings nearly 30 years of oncology and drug development experience, including successful product approvals. CEO Kimberly Blackwell highlighted his extensive expertise as pivotal for the advancement of Zentalis' pipeline, specifically azenosertib. Expected data readouts for azenosertib are anticipated throughout the remainder of 2024 and 2025, with regulatory submission planned for 2026. Dr. Walker's previous roles include VP of Clinical Development at Seagen and senior clinical roles at Cascadian Therapeutics.
Zentalis Pharmaceuticals announced the final results of its Phase 1 trial for azenosertib and gemcitabine in relapsed or refractory osteosarcoma patients, revealing a substantial improvement in event-free survival (EFS). The trial demonstrated a tripling of EFS at 18 weeks compared to historical data. Azenosertib was well tolerated, with thrombocytopenia and lymphopenia being the most common severe adverse events. The maximum tolerated dose was identified as 150 mg of azenosertib daily on a 5:2 schedule plus 800 mg/m2 of gemcitabine. The results support further investigation in a Phase 2 trial. The full data will be presented at the 2024 ASCO Annual Meeting.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer, will participate in the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, at 10:30 a.m. ET.
The event will be virtual, featuring a fireside chat with the management team. A live webcast and archived recording will be available on the company's website.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) reported its financial results for Q1 2024, showcasing progress in azenosertib clinical development plans and a strong cash position. The company highlighted upcoming milestones, corporate updates, and the projected cash runway into mid-2026. Azenosertib shows promise in various tumor types, with multiple data readouts expected in late 2024 and 2025, including results in gynecological cancers.
Zentalis Pharmaceuticals, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4), granting non-qualified stock options to three new employees. The options have an exercise price of $11.31 per share, a 10-year term, and will vest over four years.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
